Denali Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Denali Therapeutics Inc DNLI.OQ reported a quarterly adjusted loss of 72 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -59 cents. The mean expectation of eighteen analysts for the quarter was for a loss of 72 cents per share. Wall Street expected results to range from -93 cents to -43 cents per share.

• Reported revenue was zero​; analysts expected $6.47 million.

• Denali Therapeutics Inc's reported EPS for the quarter was a loss of 72 cents​.

• The company reported a quarterly loss of $124.12 million.

• Denali Therapeutics Inc shares had fallen by 0.2% this quarter and lost 31.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Denali Therapeutics Inc is $32.00, about 56.4% above its last closing price of $13.96

This summary was machine generated from LSEG data August 11 at 08:17 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)